These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 11008205

  • 1. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
    Yang JL, Seetoo Dq, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ.
    Int J Cancer; 2000 Sep 20; 89(5):431-9. PubMed ID: 11008205
    [Abstract] [Full Text] [Related]

  • 2. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, Takada A, Nakamura S.
    Cancer; 1999 Dec 15; 86(12):2602-11. PubMed ID: 10594855
    [Abstract] [Full Text] [Related]

  • 3. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P, Gao Y, Ji Z, Zhang X, Xu Q, Li G, Guo Z, Zheng B, Guo X.
    J Pediatr Surg; 2004 Oct 15; 39(10):1512-9. PubMed ID: 15486896
    [Abstract] [Full Text] [Related]

  • 4. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB.
    J Cancer Res Clin Oncol; 2000 Nov 15; 126(11):641-6. PubMed ID: 11079728
    [Abstract] [Full Text] [Related]

  • 5. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
    Plebani M, Herszènyi L, Carraro P, De Paoli M, Roveroni G, Cardin R, Tulassay Z, Naccarato R, Farinati F.
    Clin Exp Metastasis; 1997 Jul 15; 15(4):418-25. PubMed ID: 9219730
    [Abstract] [Full Text] [Related]

  • 6. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 15; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 7. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 8. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
    Nozaki S, Endo Y, Kawashiri S, Nakagawa K, Yamamoto E, Yonemura Y, Sasaki T.
    Oral Oncol; 1998 Jan 01; 34(1):58-62. PubMed ID: 9659521
    [Abstract] [Full Text] [Related]

  • 9. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 01; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 10. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
    Chambers SK, Gertz RE, Ivins CM, Kacinski BM.
    Cancer; 1995 Apr 01; 75(7):1627-33. PubMed ID: 8826920
    [Abstract] [Full Text] [Related]

  • 11. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K, Nozaki S, Kitahara H, Kato K, Noguchi N, Kawashiri S, Yamamoto E.
    Oncol Rep; 2011 Dec 01; 26(6):1555-60. PubMed ID: 21833477
    [Abstract] [Full Text] [Related]

  • 12. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V, Brünner N.
    Clin Exp Metastasis; 1996 May 01; 14(3):297-307. PubMed ID: 8674284
    [Abstract] [Full Text] [Related]

  • 13. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C, Evers C, Bache M, Reese T, Vordermark D.
    Strahlenther Onkol; 2018 Jun 01; 194(6):539-551. PubMed ID: 29340706
    [Abstract] [Full Text] [Related]

  • 14. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
    Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S.
    Cancer Sci; 2003 Jan 01; 94(1):43-9. PubMed ID: 12708473
    [Abstract] [Full Text] [Related]

  • 15. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
    Fuessel S, Erdmann K, Taubert H, Lohse-Fischer A, Zastrow S, Meinhardt M, Bluemke K, Hofbauer L, Fornara P, Wullich B, Baretton G, Magdolen V, Wirth MP, Kotzsch M.
    BMC Cancer; 2014 Dec 18; 14():974. PubMed ID: 25519168
    [Abstract] [Full Text] [Related]

  • 16. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
    Minoo P, Baker K, Baumhoer D, Terracciano L, Lugli A, Zlobec I.
    Hum Pathol; 2010 Jan 18; 41(1):70-8. PubMed ID: 19740518
    [Abstract] [Full Text] [Related]

  • 17. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan 18; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

  • 18. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS.
    J Biol Chem; 2005 Oct 28; 280(43):36529-40. PubMed ID: 16127174
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
    Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ.
    Int J Cancer; 1995 May 29; 61(5):597-600. PubMed ID: 7768629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.